Literature DB >> 25128482

The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis.

Gang Li, Fengjun Shi1, Jingchen Liu, Ye Li.   

Abstract

BACKGROUND: Recently, a number of studies have been performed to explore the association between CTLA-4 A49G polymorphism and rheumatoid arthritis (RA). However, the results of previous works are still controversial and ambiguous.
METHODS: In this work, we attempted to perform an updated meta-analysis of available case-control study in order to assess the association between CTLA-4 A49G polymorphism and RA risk. We searched the various citation databases without limits on languages. Article searching was performed by screening the references of retrieved studies manually. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to evaluate the strength of the association.
RESULTS: We totally compiled 27 studies in 24 articles (9805 RA patients and 10691 control subjects) into our meta-analysis work. We found significant association between CTL-A4 A49G polymorphism and RA risk (GG vs. AA: OR = 1.13, 95% CI = 1.03-1.23; GA vs. AA: OR = 1.19, 95% CI = 1.07-1.33; GA + GG vs. AA: OR = 1.18, 95% CI = 1.07-1.29). In the subgroup analysis by ethnicity, evidences of significantly increased risk was also found in both Asian (GG vs. AA: OR = 1.34, 95% CI = 1.15-1.55; GA + GG vs. AA: OR = 1.24, 95% CI = 1.08-1.41) and Caucasian population (GA vs. AA: OR = 1.19, 95% CI = 1.03-1.37; GA + GG vs. AA: OR = 1.14, 95% CI = 1.01-1.29). No evidence of publication bias was found in this work.
CONCLUSIONS: Our meta-analysis suggests that CTLA-4 A49G polymorphism was associated with RA risk. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_157.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25128482      PMCID: PMC4160544          DOI: 10.1186/s13000-014-0157-0

Source DB:  PubMed          Journal:  Diagn Pathol        ISSN: 1746-1596            Impact factor:   2.644


Background

Rheumatoid arthritis (RA) is a common chronic inflammatory autoimmune disease characterized by significant disability and early mortality. RA affects ~1% of the adults worldwide [1]. Although its etiology has not been determined, RA has been regarded as a complex autoimmune disorder characterized by a chronic T-cell response. So, genes involved in T-cell response regulation might be important determinants of RA susceptibility. The cytotoxic T-lymphocyte antigen 4 (CTLA-4) is an inhibitory receptor predominantly expressed on the activated and regulatory T lymphocytes [2]. It plays an important role in regulating T-cell activation. Several studies have documented that polymorphism of CTLA-4 A49G have remarkable effects on the susceptibility to autoimmunity [3]. A49G (rs231775) polymorphism, located in the first exon region of CTLA-4 gene, was identified as a functional single nucleotide polymorphism with a A to G change. This polymorphism has been shown to be associated with the susceptibility of diverse diseases [4-8], including RA. The results of previous reports on the possible association of CTLA-4 A49G polymorphism with RA risk remain controversial and ambiguous. To our knowledge, the issue of whether CTLA-4 A49G polymorphism can increase RA risk remains largely uncertain. A comprehensive meta-analysis can provide a reliable estimate in genetic association studies. In this work, we conducted a quantitative meta-analyses that increased statistical power to derive a more precise estimation of the relationship.

Methods

Study identification and selection

A systematic literature search was carried out in the PubMed, IS Web and Chinese National Knowledge Infrastructure (CNKI) database with the terms of “CTLA-4”, “rheumatoid arthritis”, “polymorphism”, “variation”. Two investigators independently screened the information including the titles, abstracts and full texts to determine inclusion carefully. No language restrictions were used in our literature search.

Data extraction

The following inclusion criteria were used to select related literatures for the meta-analysis: (1) studies about the association between CTLA-4 A49G polymorphism and RA risk; (2) a case-controlled RA study of CTLA-4 A49G polymorphism with complete genotype distribution data; (3) studies on sufficient data and the original data from case–control studies. The following information were extracted from included studies: first author, year of publication, original country, ethnicity of the sample and genotype distributions.

Statistical analysis

The pooled odds ratios (ORs) with the corresponding 95% confidence intervals (95% CI) were used to evaluate the strength of association between the polymorphism of CTLA-4 A49G and RA risk. Four models were estimated: the co-dominant model (GG vs. AA, GA vs. AA), dominant model (GA + GG vs. AA) and recessive model (GG vs. GA + AA), respectively. Subgroup analyses were performed by ethnicity. At first, we evaluated the HWE in the controls for each study using chi-square and a P < 0.05 was considered as significant disequilibrium. Statistical heterogeneity among the studies was gauged by the Chi-square based on Q-test. A P value greater than 0.1 for the Q-test indicates no significant heterogeneity existing among studies, and the pooled OR estimation was performed using the fixed-effects model (the Mantel-Haenszel method). Otherwise, the random-effects model (DerSimonian and Laird method) was used. Potential publication bias of literatures was analyzed through the Egger’s linear regression test with a funnel plot. All statistical analyses were performed with STATA version 11.0 (Stata Corporation, College Station, TX). All the P values were calculated using a two-sided test and P < 0.05 were considered as statistically significant.

Results

Study characteristics

A total of xx articles were retrieve after the first search in various databases. After literature selection, 43 studies about the association of CTLA-4 A49G polymorphism with RA risk were identified and screened for data retrieval. Among which, 16 studies were irrelevant. At last, a total of 27 eligible independent case–control studies in 24 articles were included [9-33]. The characteristics of selected studies are summarized in Table 1. All of the studies indicated that the genotypic distribution of the controls was consistent with Hardy-Weinberg equilibrium.
Table 1

Main characteristics of studies included in our work

First author Year Location Ethnicity Case/controls HWE
GG GA AA
Seidl1998GermanyCaucasian37/68138/21083/1790.88
Matsushita1999JapanAsian200/56199/7262/220.98
Gonzalez-Escribano1999SpainCaucasian10/3063/10365/1720.06
Barton2000SpainCaucasian14/1257/7065/620.44
Yanagawa2000JapanAsian29/7850/886/340.56
Hadj2001TunisiaAfrican23/6827/6210/200.33
Milicic2001UKCaucasian63/73223/213135/1660.94
Lee2002KoreaAsian41/4935/2910/80.49
Vaidya2002UKCaucasian20/4565/15838/1460.97
Lee2003ChinaAsian103/8567/10016/180.32
Liu2004TaiwanAsian14/2142/509/100.07
Barton2004UKCaucasian34/2955/6843/590.49
Lei2005ChinaAsian148/86138/12540/390.84
Takeuchi2006JapanAsian49/4439/4912/110.88
Suppiah2006UKCaucasian40/92144/24192/1420.85
Tsukahara2008JapanAsian636/181668/194186/730.23
Walker2009CanadaCaucasian177/179554/576409/4930.87
Munoz-Valle2010MexicoMexican42/34102/8255/830.22
Plant (F)2010FranceCaucasian96/15315/75273/720.77
Plant (Ge)2010GermanyCaucasian37/94111/8372/830.44
Plant (Gr)2010GreeceCaucasian26/33133/107113/1470.15
Plant (U)2010UKCaucasian146/410451/1255407/9940.91
Benhatchi2011SlovakiaCaucasian6/533/2518/210.82
Rocha2011BrailCaucasian9/329/1532/120.86
Tang2013ChinaAsian652/474642/535195/1910.154
Alfadhli2013KuwaitAsian10/1430/8674/1820.65
Liu2013ChinaAsian77/130111/12525/480.16
Main characteristics of studies included in our work

Quantitative synthesis

All of the main results of the meta-analysis were shown in Table 2. Overall, significant associations between CTLA-4 A49G polymorphism and RA risk was found (GG vs. AA: OR = 1.13, 95% CI = 1.03–1.23; GA vs. AA: OR = 1.19, 95% CI = 1.07–1.33; GA + GG vs. AA: OR = 1.18, 95% CI = 1.07–1.29) (Figure 1). Next, we performed a further analysis on data stratified by ethnicity groups with the attempt to search for possible factors that might impact the results. In the subgroup analysis by ethnicity, evidences of significantly increased risk was also found in both Asian (GG vs. AA: OR = 1.34, 95% CI = 1.15–1.55; GA + GG vs. AA: OR = 1.24, 95% CI = 1.08–1.41) and Caucasian population (GA vs. AA: OR = 1.19, 95% CI = 1.03–1.37; GA + GG vs. AA: OR = 1.14, 95% CI = 1.01–1.29) in different genetic models.
Table 2

Results of meta-analysis for CTLA-4 A49G polymorphism and RA risk

Groups GG vs AA GA vs AA GA + GG vs AA GG vs GA + AA
P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI)
Total0.0091.13 (1.03, 1.23)0.0011.19 (1.07, 1.33)0.0011.18 (1.07, 1.29)0.661.03 (0.91, 1.17)
Asians0.0011.34 (1.15, 1.55)0.0831.16 (0.98, 1.37)0.0021.24 (1.08, 1.41)0.0991.14 (0.97, 1.35)
Caucasian0.9911.00 (0.89, 1.12)0.0151.19 (1.03, 1.37)0.0421.14 (1.01, 1.29)0.510.93 (0.77, 1.14)
Figure 1

Forest plots for the overall association between CTLA-4 A49G polymorphism and RA risk A) GG AA; B) GA AA; C) GA + GG AA; D) GG GA + GG.

Results of meta-analysis for CTLA-4 A49G polymorphism and RA risk Forest plots for the overall association between CTLA-4 A49G polymorphism and RA risk A) GG AA; B) GA AA; C) GA + GG AA; D) GG GA + GG.

Heterogeneity analysis

Significant heterogeneity existed in all four genetic models (GG vs. AA: P = 0.016, I = 40.7%; GA vs. AA: P = 0.01, I = 42.9%; GA + GG vs. AA: P = 0.027, I = 37.4%; GG vs. GA + AA: P = 0.00, I = 58.2%). Therefore, the random-effect models were employed in all genetic models.

Sensitivity analyses and publication bias

Sensitivity analyses were performed to assess whether each individual study can affect the final results by using Begg’s test and Egger’s test. Neither the Begg’s test nor the Egger’s test provided any obvious evidences of publication bias (Table 3). The shapes of the funnel plots appeared to be symmetrical in all genetic models (Figure 2). These results showed that no individual study affected the final results in diverse genetic models using the exclusion method step by step.
Table 3

Results of Egger’s test and Begg’s test

Comparison Egger’s test Begg’s test
t P 95% CI Z P
GG vs AA0.310.76(−0.92, 1.25)0.670.51
GA vs AA1.020.32(−0.54, 1.61)0.330.74
GA + GG vs AA1.070.29(−0.49, 1.55)0.670.51
GG vs GA + AA−0.550.58(−1.62, 0.94)0.080.93
Figure 2

Funnel plots for A49G polymorphism of CTLA-4 in RA disease A) GG AA; B) GA AA; C) GA + GG AA; D) GG GA + GG.

Results of Egger’s test and Begg’s test Funnel plots for A49G polymorphism of CTLA-4 in RA disease A) GG AA; B) GA AA; C) GA + GG AA; D) GG GA + GG.

Discussion

Although many efforts have been devoted for decades, the underlying molecular genetic basis of RA remains largely unknown. Recently, researches in the genetic susceptibility to RA have led to growing attentions to the study of association between gene polymorphisms and RA [34]. Large and well-designed genotype-phenotype investigations with robust statistical technical are required to detect these mild to moderate associations. Up to date, the association studies have been performed for CTLA-4 A49G polymorphism with respect to several disease susceptibility, such as liver disease, pancreatic cancer, primary biliary cirrhosis, etc. [5,35,36]. It has been realized that CTLA-4 A49G polymorphism play important role in disease disorders. Several case–control studies have demonstrated inconsistent and even inverse relationship between CTLA-4 A49G polymorphism and RA risk. Until now, there are still no consensus results on the association of CTLA-4 A49G polymorphism and susceptibility of RA. In this work, we conducted a more comprehensive meta-analysis on the CTLA-4 A49G polymorphism and RA. For the overall data, it has been shown that CTLA-4 A49G polymorphism have an elevated association with RA risk. In the subgroup analysis by ethnicity, results suggested that strong evidences support the association between RA risk and CTLA-4 A49G polymorphism in both Asian and Caucasian populations. Previous meta-analyses works have reported that the CTLA-4 A49G polymorphism is associated with RA risk in Asians, but not in Caucasians using limited data [37,38]. In our work, we performed an up-dated meta-analyses, and found that A49G polymorphism is associated with RA risk in both Asians and Caucasians. Many works have been devoted to examine the association between polymorphisms and RA risk [39,40]. As we know, genetic polymorphism of biomarkers is the key factor leading to the susceptibility of diseases. Our work suggests that CTLA-4 A49G polymorphism might be a potential clinical marker for RA. Important clinical insights are emerging, and this polymorphism provides new understanding of RA diagnostic advances. We provided useful reference for clinical medical treatment. However, there are still some limitations in our meta-analysis work. First, we were not able to take into account other factors because of lacking the original data, such as alcohol addictive, inflammation and other disease that may influence the association estimates; Second, although all eligible studies were summarized, the total sample size might have not been enough to make a convincing conclusion. So, when we performed stratified analysis of ethnicity, the number of each subgroup was relative smaller.

Conclusions

Our meta-analyses provided a more comprehensive evidence of the association between CTLA-4 A49G polymorphism and RA risk. The result showed that CTLA-4 A49G polymorphism is associated with susceptibility of RA.
  39 in total

1.  CTLA-4 CT60 polymorphism is not an independent genetic risk marker of rheumatoid arthritis in a Japanese population.

Authors:  S Tsukahara; T Iwamoto; K Ikari; E Inoue; T Tomatsu; M Hara; H Yamanaka; N Kamatani; S Momohara
Journal:  Ann Rheum Dis       Date:  2008-03       Impact factor: 19.103

2.  Genetic polymorphisms and surface expression of CTLA-4 and PD-1 on T cells of silica-exposed workers.

Authors:  Michelle C Rocha; Leonilda M B Santos; Ericson Bagatin; Jan W Cohen Tervaert; Jan G M C Damoiseaux; Alessandro V Lido; Ana L Longhini; Cristiane O Torello; Mary L S Queiroz
Journal:  Int J Hyg Environ Health       Date:  2011-12-05       Impact factor: 5.840

3.  No association of polymorphisms of the CTLA-4 exon 1(+49) and promoter(-318) genes with rheumatoid arthritis in the Korean population.

Authors:  Young Ho Lee; Seong Jai Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Scand J Rheumatol       Date:  2002       Impact factor: 3.641

4.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

Authors:  Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S Babb; James P Allison; Silvia C Formenti
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

5.  Geographic variation in rheumatoid arthritis incidence among women in the United States.

Authors:  Karen H Costenbader; Shun-Chiao Chang; Francine Laden; Robin Puett; Elizabeth W Karlson
Journal:  Arch Intern Med       Date:  2008-08-11

6.  Association of CTLA4 gene A-G polymorphism with rheumatoid arthritis in Chinese.

Authors:  C-S Lee; Y-J Lee; H-F Liu; C-H Su; S-C Chang; B-R Wang; T-L Chen; T-L Liu
Journal:  Clin Rheumatol       Date:  2003-09       Impact factor: 2.980

7.  CTLA-4 and CD86 genetic variants and haplotypes in patients with rheumatoid arthritis in southeastern China.

Authors:  C-P Liu; J-A Jiang; T Wang; X-M Liu; L Gao; R-R Zhu; Y Shen; M Wu; T Xu; X-G Zhang
Journal:  Genet Mol Res       Date:  2013-04-25

8.  CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian population.

Authors:  Erin J Walker; Gideon M Hirschfield; Chun Xu; Yan Lu; Xiangdong Liu; Yue Lu; Catalina Coltescu; Kesheng Wang; William G Newman; Vivian Bykerk; Edward C Keystone; Dianne Mosher; Christopher I Amos; E Jenny Heathcote; Katherine A Siminovitch
Journal:  Arthritis Rheum       Date:  2009-04

9.  Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer.

Authors:  Adam Antczak; Dorota Pastuszak-Lewandoska; Paweł Górski; Daria Domańska; Monika Migdalska-Sęk; Karolina Czarnecka; Ewa Nawrot; Jacek Kordiak; Ewa Brzeziańska
Journal:  Biomed Res Int       Date:  2013-07-09       Impact factor: 3.411

10.  Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.

Authors:  Satoshi Wada; Christopher M Jackson; Kiyoshi Yoshimura; Hung-Rong Yen; Derese Getnet; Timothy J Harris; Monica V Goldberg; Tullia C Bruno; Joseph F Grosso; Nicholas Durham; George J Netto; Drew M Pardoll; Charles G Drake
Journal:  J Transl Med       Date:  2013-04-04       Impact factor: 5.531

View more
  11 in total

1.  Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.

Authors:  Sanjay S Shete; Maria E Suarez-Almazor; Noha Abdel-Wahab; Adi Diab; Robert K Yu; Andrew Futreal; Lindsey A Criswell; Jean H Tayar; Ramona Dadu; Vickie Shannon
Journal:  Cancer Immunol Immunother       Date:  2021-01-07       Impact factor: 6.968

2.  CD28, CTLA-4 and CCL5 gene polymorphisms in patients with rheumatoid arthritis.

Authors:  Katarzyna Luterek-Puszyńska; Damian Malinowski; Agnieszka Paradowska-Gorycka; Krzysztof Safranow; Andrzej Pawlik
Journal:  Clin Rheumatol       Date:  2016-12-17       Impact factor: 2.980

Review 3.  Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects.

Authors:  Mahendra Kumar Verma; Kota Sobha
Journal:  Inflamm Res       Date:  2015-07-07       Impact factor: 4.575

4.  Role and mechanism of vascular cell adhesion molecule-1 in the development of rheumatoid arthritis.

Authors:  Laifang Wang; Yanjie Ding; Xiaqing Guo; Qing Zhao
Journal:  Exp Ther Med       Date:  2015-07-15       Impact factor: 2.447

5.  Association between CTLA-4 rs231775 polymorphism and hepatocellular carcinoma susceptibility.

Authors:  Zhao Liu; Zhao Song; Jing Sun; Fenglei Sun; Chuanzhi Li; Jiuzheng Sun; Liyou Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

6.  Impact of cytotoxic T-lymphocyte-associated protein 4 codon 17 variant and expression on vitiligo risk.

Authors:  Nawal S Gouda; Manal S Fawzy; Eman A Toraih
Journal:  J Clin Lab Anal       Date:  2021-05-01       Impact factor: 2.352

7.  The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis.

Authors:  Takayoshi Morita; Yoshihito Shima; James Badger Wing; Shimon Sakaguchi; Atsushi Ogata; Atsushi Kumanogoh
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240

Review 8.  Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response.

Authors:  Dmitry S Mikhaylenko; Marina V Nemtsova; Irina V Bure; Ekaterina B Kuznetsova; Ekaterina A Alekseeva; Vadim V Tarasov; Alexander N Lukashev; Marina I Beloukhova; Andrei A Deviatkin; Andrey A Zamyatnin
Journal:  Int J Mol Sci       Date:  2020-07-11       Impact factor: 5.923

9.  CTLA-4 rs231775 and risk of acute renal graft rejection: an updated meta-analysis with trial sequential analysis.

Authors:  Sarah Cargnin; Ubaldina Galli; Jae Il Shin; Salvatore Terrazzino
Journal:  Sci Rep       Date:  2020-07-30       Impact factor: 4.379

Review 10.  The Role of CTLA4 and Its Polymorphisms in Solid Organ and Haematopoietic Stem Cell Transplantation.

Authors:  Jakub Rosik; Bartosz Szostak; Filip Machaj; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.